Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Abstract : Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis.
Complete list of metadatas

https://hal.univ-brest.fr/hal-02052475
Contributor : Ghislaine Calvez <>
Submitted on : Thursday, February 28, 2019 - 2:43:05 PM
Last modification on : Friday, March 1, 2019 - 1:26:32 AM

Identifiers

Collections

Citation

Marc Carrier, Karim Abou-Nassar, Ranjeeta Mallick, Vicky Tagalakis, Sudeep Shivakumar, et al.. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, Massachusetts Medical Society, 2019, 380 (8), pp.711-719. ⟨10.1056/NEJMoa1814468⟩. ⟨hal-02052475⟩

Share

Metrics

Record views

31